Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer
Shicheng Su(Sun Yat-sen University), Erwei Song(Sun Yat-sen University), Nengtai Ouyang(Sun Yat-sen University), Wei Wu(Anhui Agricultural University), Chonghua He(Sun Yat-sen University), Herui Yao(Sun Yat-sen University), Jiang Liu(Sun Yat-sen University), Fei Chen(Fuzhou University), Qiang Liu(Sun Yat-sen University), Jianing Chen(Fujian University of Technology), Ling Lin(Huazhong University of Science and Technology), Fengxi Su(Sun Yat-sen University), Yunjie Zeng(Sun Yat-sen University), Xiuying Cui(Sun Yat-sen University), Langyi Yang(Sun Yat-sen University), Judy Lieberman(Boston Children's Hospital), Jian‐Dong Huang(Sun Yat-sen University), Di Huang(South China Agricultural University)
Cited by 225
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing
|Clinical Infectious Diseases|2020|818
Channelling inflammation: gasdermins in physiology and disease
|Nature Reviews Drug Discovery|2021|747
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells
|Molecular Cancer|2011|700